EP0759036A4 - Immunointeractive molecules-i - Google Patents

Immunointeractive molecules-i

Info

Publication number
EP0759036A4
EP0759036A4 EP95910971A EP95910971A EP0759036A4 EP 0759036 A4 EP0759036 A4 EP 0759036A4 EP 95910971 A EP95910971 A EP 95910971A EP 95910971 A EP95910971 A EP 95910971A EP 0759036 A4 EP0759036 A4 EP 0759036A4
Authority
EP
European Patent Office
Prior art keywords
immunointeractive molecules
immunointeractive
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95910971A
Other languages
German (de)
French (fr)
Other versions
EP0759036A1 (en
Inventor
Andrew Frederick Wilks
Steven Alan Stacker
Robert Brenchley Oelrichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP0759036A1 publication Critical patent/EP0759036A1/en
Publication of EP0759036A4 publication Critical patent/EP0759036A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
EP95910971A 1994-02-10 1995-02-09 Immunointeractive molecules-i Withdrawn EP0759036A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM3793A AUPM379394A0 (en) 1994-02-10 1994-02-10 Immunointeractive molecules - i
AUPM3793/94 1994-02-10
PCT/US1995/001727 WO1995021865A1 (en) 1994-02-10 1995-02-09 Immunointeractive molecules-i

Publications (2)

Publication Number Publication Date
EP0759036A1 EP0759036A1 (en) 1997-02-26
EP0759036A4 true EP0759036A4 (en) 1999-12-01

Family

ID=3778411

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95910971A Withdrawn EP0759036A4 (en) 1994-02-10 1995-02-09 Immunointeractive molecules-i

Country Status (5)

Country Link
EP (1) EP0759036A4 (en)
JP (1) JPH09509414A (en)
AU (1) AUPM379394A0 (en)
CA (1) CA2182682A1 (en)
WO (1) WO1995021865A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
NZ300808A (en) * 1994-12-23 1999-04-29 Ludwig Inst Cancer Res A method of detecting a ligand capable of binding the receptor protein nyk
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
WO1999040118A1 (en) * 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Antibodies against human vegf receptor kdr
CN101966338A (en) 2003-06-09 2011-02-09 塞缪尔·瓦克萨尔 Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
KR100883430B1 (en) 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010136A1 (en) * 1991-11-15 1993-05-27 The Trustees Of Princeton University Totipotent hematopoietic stem cell receptors and their ligands
WO1994010202A1 (en) * 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994011499A1 (en) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 is a receptor for vascular endothelial growth factor
WO1995021868A1 (en) * 1994-02-10 1995-08-17 Imclone Systems Incorporated Monoclonal antibodies specific to vegf receptors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010136A1 (en) * 1991-11-15 1993-05-27 The Trustees Of Princeton University Totipotent hematopoietic stem cell receptors and their ligands
WO1994010202A1 (en) * 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994011499A1 (en) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 is a receptor for vascular endothelial growth factor
WO1995021868A1 (en) * 1994-02-10 1995-08-17 Imclone Systems Incorporated Monoclonal antibodies specific to vegf receptors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROCKWELL, P. ET AL: "In vitro neutralization of vascular endothelial growth factor activation of FLK - 1 by a monoclonal antibody.", MOLECULAR BIOLOGY OF THE CELL, (1994) VOL. 5, NO. SUPPL., PP. 383A. MEETING INFO.: THIRTY-FOURTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY SAN FRANCISCO, CALIFORNIA, USA DECEMBER 10-14, 1994, XP002116505 *
See also references of WO9521865A1 *

Also Published As

Publication number Publication date
AUPM379394A0 (en) 1994-03-03
EP0759036A1 (en) 1997-02-26
CA2182682A1 (en) 1995-08-17
JPH09509414A (en) 1997-09-22
WO1995021865A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
DE69531947D1 (en) Ausbreitbare ringprothese
DE69512030D1 (en) Cerebral-dilator
EP0696731A3 (en) Cytoanalyzer
DE59503739D1 (en) Polymer-sensor
AUPM379494A0 (en) Immunointeractive molecules - ii
DE69529159D1 (en) Hüftgelenkprothese
DE69502271D1 (en) Afterabtrennung
DE69511086D1 (en) Pyrimidinderivate
DE69504528D1 (en) Quenchkühler
DE69429543D1 (en) Koagulationszange
DE59503634D1 (en) Friercontainer
EP0701109A3 (en) Watermeter
DE69512382D1 (en) Deodorierte thermoplaste
DE59509661D1 (en) Heterocyclylbenzonitrile
EP0759036A4 (en) Immunointeractive molecules-i
DE69517588D1 (en) Gekühlter transportcontainer
DE69517886D1 (en) Spiropyranverbindung
AU122938S (en) Breadbox
DE69508761D1 (en) Haloalkylierungsverfahren
DE69506730D1 (en) Differentialer antriebsmechanismus
DE69527047D1 (en) Bisazoverbindung
DE59508136D1 (en) Phenylthio-oxazolin-derivate
DE59510739D1 (en) N-cyanoaryl-stickstoffheterocyclen
DE59503452D1 (en) Piezoresistiver widerstand
DE69504062D1 (en) Spandexlieferspule

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991013

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010510

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010921